A study presented at this year’s meeting of the European Association for the Study of Diabetes showed that diabetic patients who use insulin therapy guided by Glytec‘s Glucommander software achieved glucose control quickly and successfully maintained A1C reductions long-term, the company reported today. Once a patient gets their blood sugar into range, the Glucommander software […]
Diabetes
ALR Technologies’ insulin dose adjustment feature wins FDA approval
ALR Technologies said today that the FDA approved the insulin dose adjustment feature of its ALRT diabetes management system. The ALRT system uses insulin dosing guidelines from the American Association of Clinical Endocrinologists and American Diabetes Association as reference doses. The reference doses are compared with a patient’s current insulin dose to decide if a patient’s […]
Dexcom launches program to connect CGM data with 3rd-party apps
Dexcom (NSDQ:DXCM) today launched a public API that allows 3rd-party developers to connect patient-authorized continuous glucose monitoring data into software apps. The data-sharing platform is designed to make use of the blood glucose data produced by Dexcom’s CGM systems. Companies, including One Drop, have begun accessing the API and others in the U.S. can register online, […]
Arkray launches diabetes diagnostic tech
Arkray‘s U.S. subsidiary launched today its Adams A1c HA-8180V system for hemoglobin A1c testing. The device is indicated to help diagnose and monitor people with diabetes, the Edina, Minn.-based company reported. “We are excited to bring this technology to the U.S. market. The ADAMS A1c HA-8180V builds on proven expertise. The Adams brand has been used globally […]
Microneedle skin patch delivers fat-burning drug in mouse trial
Researchers have created a drug-filled microneedle skin patch that helps convert energy-storing fat, or white fat, into energy-burning fat, or brown fat – all the while boosting the body’s metabolism. The team of researchers at Columbia University Medical Center and the University of North Carolina reported that their patch could one day be used to burn […]
Livongo buys diabetes management company Diabeto
Livongo Health said yesterday that it bought digital diabetes management company, Diabeto, for an undisclosed amount. Diabeto sells a connectivity technology called Birdie that plugs into more than 40 different glucose meters, connecting them to Diabeto’s mobile apps and to Livongo’s newly-released apps. “We’ve heard from the market that, in addition to a comprehensive solution […]
Study: 30% of T2D patients don’t start insulin therapy when recommended
Research from Brigham & Women’s Hospital, supported by Sanofi (NYSE:SNY), found that 30% of people with Type II diabetes don’t begin insulin therapy when it’s first recommended to them. On average, these patients are delaying treatment by two years, the researchers reported. The team’s work was published in the journal of Diabetic Medicine. “Unfortunately this isn’t uncommon, […]
Sanofi touts patient-driven dose titration of Toujeo insulin glargine injection
Sanofi (NYSE:SNY) today touted data from the Take Control trial of its Toujeo insulin glargine product in patients with Type II diabetes. The study compared patients using Toujeo with a titration algorithm managed by the patient, compared to patients whose dose adjustment was decided by their physicians. The 631-patient trial revealed that after six months, patients […]
Sanofi’s Toujeo beats Lantus at stabilizing blood sugar in T2D patients
Adults with Type II diabetes treated with Sanofi‘s (NYSE:SNY) Toujeo Gla-300 insulin glargine had better blood glucose stability than those treated with the company’s Lantus Gla-100 insulin glargine product, according to a study presented at the annual meeting of the European Association for the Study of Diabetes. The analysis re-analyzed patient data from the Edition […]
Insulet touts real-world data for Omnipod insulin management tech
Insulet (NSDQ:PODD) touted real-world data today for its Omnipod insulin management system at the Congress of the European Association for the Study of Diabetes. The data come from a study of nearly 39,000 patients with Type I and Type II diabetes who received insulin through the Omnipod system and had at least three months of data […]